Table 1.
Clinical and tumor characteristics of patients with high-risk localized or locally advanced prostate cancer enrolled in our phase II trial
| Variable | Cohort 1 (n=18) | Cohort 2 (n=17) | |
|---|---|---|---|
| Age, years, median (IQR) |
59 (56–63) |
69 (67–73) |
|
| Serum PSA level, ng/ml, median (IQR) |
17 (8–26) |
18 (9–28) |
|
| Clinical T stage, n |
T2 |
6 |
5 |
| T3 |
12 |
11 |
|
| T4 |
0 |
1 |
|
| Clinical N stage, n |
N0 |
16 |
15 |
| N+ |
2 |
2 |
|
| Biopsy Gleason score, n |
6 |
3 |
2 |
| 3+4 |
1 |
2 |
|
| 4+3 |
4 |
7 |
|
| 8-10 |
9 |
6 |
|
| Pathological T stage*, n |
T2c |
2 |
NA |
| T3a |
3 |
||
| T3b |
11 |
||
| T4 |
2 |
||
| Positive lymph node status, n |
4 |
NA |
|
| Positive surgical margins, n |
8 |
NA |
|
| Pathological Gleason score, n |
8 |
5 |
NA |
| 9 |
13 |
||
| Follow up, months, median (IQR) | 61 (45–80) | 63 (26–77) | |
IQR = interquartile range; NA = not applicable; PSA = prostate specific antigen; *according to the 2002 TNM classification.